Efficacy and safety of insulin degludec given as part of basal - bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomised, open-label, treat-to-target non-inferiority trial.

CONCLUSION: IDeg administered OD in basal-bolus therapy effectively improved long-term glycaemic control in participants with T1DM with a lower risk of nocturnal confirmed hypoglycaemia than IDet. PMID: 24702700 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24702700?dopt=Abstract

Source: Diabetes Metab - April 7, 2014 Category: Endocrinology Authors: Davies MJ, Gross JL, Ono Y, Sasaki T, Bantwal G, Gall MA, Niemeyer M, Seino H Tags: Diabetes Obes Metab Source Type: research